Early infection screening for full-term newborns
Part of Genetic & congenital, Infections clinical trials.
This study looks at a new way to decide if a newborn might have an infection and needs treatment. It may help avoid unnecessary treatments for babies who are not really infected.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your baby was born at Hillel Yaffe Medical Center
- Your baby is at least 35 weeks along in the pregnancy (full-term or close to it)
- A blood test was taken from your baby to check for infection
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing ways to make the best treatment decisions for newborns who may have an early infection (sepsis). It focuses on babies born at 34 weeks or later and within their first three days of life.
This study is testing a new blood test to see if it can help doctors decide when to use antibiotics for newborns who may have a late-onset infection. The goal is to reduce unnecessary antibiotic use.
This study tests a faster way to check premature babies for infection using a small blood sample taken shortly after birth. It aims to help doctors detect and treat infections earlier.
This study checks if a blood test (presepsin) can help doctors safely stop antibiotics earlier in preterm babies at moderate risk of infection. The goal is to reduce unnecessary antibiotic use.
This study looks at two simple blood tests (CBC and lactate) in newborns with signs of infection. These tests may help doctors find sepsis faster and guide treatment.
This study checks pregnant women in their first trimester for infections of the lower genital tract, which might help detect and treat issues early to keep both mother and baby healthy.
Hear when a new Neonatal Early-onset Sepsis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.